CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs
- PMID: 20847137
- DOI: 10.1124/dmd.110.034140
CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs
Abstract
CYP3A4, the major form of cytochrome P450 (P450) expressed in the adult human liver, is involved in the metabolism of approximately 50% of commonly prescribed drugs. Several genetic polymorphisms in CYP3A4 are known to affect its catalytic activity and to contribute in part to interindividual differences in the pharmacokinetics and pharmacodynamics of CYP3A4 substrate drugs. In this study, catalytic activities of the two alleles found in East Asians, CYP3A4*16 (T185S) and CYP3A4*18 (L293P), were assessed using the following seven substrates: midazolam, carbamazepine, atorvastatin, paclitaxel, docetaxel, irinotecan, and terfenadine. The holoprotein levels of CYP3A4.16 and CYP3A4.18 were significantly higher and lower, respectively, than that of CYP3A4.1 when expressed in Sf21 insect cell microsomes together with human NADPH-P450 reductase. CYP3A4.16 exhibited intrinsic clearances (V(max)/K(m)) that were lowered considerably (by 84-60%) for metabolism of midazolam, carbamazepine, atorvastatin, paclitaxel, and irinotecan compared with CYP3A4.1 due to increased K(m) with or without decreased V(max) values, whereas no apparent decrease in intrinsic clearance was observed for docetaxel. On the other hand, K(m) values for CYP3A4.18 were comparable to those for CYP3A4.1 for all substrates except terfenadine; but V(max) values were lower for midazolam, paclitaxel, docetaxel, and irinotecan, resulting in partially reduced intrinsic clearance values (by 34-52%). These results demonstrated that the impacts of both alleles on CYP3A4 catalytic activities depend on the substrates used. Thus, to evaluate the influences of both alleles on the pharmacokinetics of CYP3A4-metabolized drugs and their drug-drug interactions, substrate drug-dependent characteristics should be considered for each drug.
Similar articles
-
Functional characterization of CYP3A4.16: catalytic activities toward midazolam and carbamazepine.Xenobiotica. 2009 Feb;39(2):140-7. doi: 10.1080/00498250802617746. Xenobiotica. 2009. PMID: 19255940
-
Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone.Drug Metab Dispos. 2008 Nov;36(11):2287-91. doi: 10.1124/dmd.108.021816. Epub 2008 Jul 31. Drug Metab Dispos. 2008. PMID: 18669585
-
The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin.Drug Metab Dispos. 2003 Jan;31(1):53-9. doi: 10.1124/dmd.31.1.53. Drug Metab Dispos. 2003. PMID: 12485953
-
Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients.Cancer Treat Rev. 2013 Nov;39(7):773-83. doi: 10.1016/j.ctrv.2012.12.008. Epub 2013 Feb 8. Cancer Treat Rev. 2013. PMID: 23394826 Review.
-
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.Clin Pharmacokinet. 2005;44(3):279-304. doi: 10.2165/00003088-200544030-00005. Clin Pharmacokinet. 2005. PMID: 15762770 Review.
Cited by
-
Resistance to TOP-1 Inhibitors: Good Old Drugs Still Can Surprise Us.Int J Mol Sci. 2023 Apr 13;24(8):7233. doi: 10.3390/ijms24087233. Int J Mol Sci. 2023. PMID: 37108395 Free PMC article. Review.
-
Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration-resistant prostate cancer.Prostate Int. 2015 Jun;3(2):51-5. doi: 10.1016/j.prnil.2015.03.002. Epub 2015 Mar 17. Prostate Int. 2015. PMID: 26157768 Free PMC article.
-
Enzymatic Activities of CYP3A4 Allelic Variants on Quinine 3-Hydroxylation In Vitro.Front Pharmacol. 2019 May 31;10:591. doi: 10.3389/fphar.2019.00591. eCollection 2019. Front Pharmacol. 2019. PMID: 31214030 Free PMC article.
-
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA.Oncologist. 2014 Jul;19(7):693-701. doi: 10.1634/theoncologist.2014-0033. Epub 2014 May 28. Oncologist. 2014. PMID: 24869931 Free PMC article. Clinical Trial.
-
Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.Clin Pharmacokinet. 2018 Oct;57(10):1307-1323. doi: 10.1007/s40262-018-0631-z. Clin Pharmacokinet. 2018. PMID: 29626326
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources